All In Biotech

Drug Trial Radar · NCT06781281

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Neoadjuvant NabPE With or Without Serplulimab for Early-stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Breast cancer-an Observational Real-world Study.

Last checked: Nov 19, 2026Latest source record: Jun 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

709

Planned (sponsor's estimate)

Start

Dec 4, 2024

Primary completion

Nov 28, 2026

Study completion Nov 28, 2030

Sponsor

Lead sponsor
Henan Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn if serplulimab is effective in early HR+/HER2- breast cancer. This trial serves a prospective parallel control cohort for HELEN-018 (NCT). The main questions it aims to answer are: Does serplulimab combined with neoadjuvant chemotherapy improve the pCR rate of early HR+/HER2- breast cancer? What medical problems do participants have when receiving serplulimab? Researchers will compare the effect of serplulimab combined with chemotherapy to the effect of chemotherapy reported in literature. Participants will: Receive serplulimab plus chemotherapy every 3 weeks for 6 cycles; All patients will receive surgery, and the primary end point is a pathological complete response at the time of definitive surgery; After definitive surgery, the participants will receive adjuvant serplulimab every 3 weeks for up to 6 months from the begining of the treatment.

Conditions

  • Breast Cancer Invasive

Interventions

  • SerplulimabDrug

    Serplulimab

  • NabPEDrug

    Epirubicin 75mg/m2 ivgtt +Albumin Paclitaxel 260mg/m2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pathological complete responseTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan cancer hospital

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.